Literature DB >> 6524300

Neuropathology of the Norrbottnian type of Gaucher disease. Morphological and biochemical studies.

N G Conradi, P Sourander, O Nilsson, L Svennerholm, A Erikson.   

Abstract

The Norrbottnian type of Gaucher disease is characterized by infantile or juvenile onset and variable degrees of neurological symptoms, some of which develop only after splenectomy. A full neuropathological description of this type of Gaucher disease has not been reported previously. The brains of five patients were examined morphologically and biochemically. All presented typical accumulations of glucosylceramide storing cells in the adventitia of vessels in the cerebral and cerebellar sub-cortical white matter (s.c.w.m.). There were differences between the five cases with regard to the accumulation of adventitial storage cells and to the fatty acid pattern of the glucosylceramide isolated from the s.c.w.m., which implicate that the accumulation of glucosylceramide in adventitial cells in the brain is dependent on the generalized lipid storage process and enhanced by splenectomy. Loss of neurones and myelin was noted in the vicinity of accumulations of storage cells in two cases. The five cases showed varying degrees of nerve cell loss, satellitosis and neuronophagia. Lipofuscin with simple and complex lipids but no glycolipids could be demonstrated in neurones light-microscopically. Ultrastructural examination revealed inclusion bodies with bilayers in neurones of the cerebral and cerebellar cortex, dentate nucleus and pons. Because of the bilayered structure of Gaucher cell inclusions the bilayers in neurones are assumed to be formed by glucosylceramide. The fatty acid composition of glucosylceramide isolated from cerebral cortex in all cases suggested that cerebral gangliosides were its main precursor. The highest levels of psychosine (glucosylsphingosine) were seen in the cases with the most advanced nerve cell loss. The morphological and biochemical findings indicate that the neuronopathic process is associated with accumulation of glucosylceramide and psychosine in neurones.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6524300     DOI: 10.1007/bf00690463

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  17 in total

1.  A case of juvenile Gaucher's disease with intraneuronal lipid storage.

Authors:  A F MALONEY; J N CUMINGS
Journal:  J Neurol Neurosurg Psychiatry       Date:  1960-08       Impact factor: 10.154

2.  The bilayer nature of deposits occurring in Gaucher's disease.

Authors:  R E Lee; C R Worthington; R H Glew
Journal:  Arch Biochem Biophys       Date:  1973-11       Impact factor: 4.013

3.  Gaucher disease in mice induced by conduritol-B-epoxide: morphologic features.

Authors:  M Adachi; B W Volk
Journal:  Arch Pathol Lab Med       Date:  1977-05       Impact factor: 5.534

4.  Gaucher disease--Norrbottnian type. Neurodevelopmental, neurological, and neurophysiological aspects.

Authors:  S Blom; A Erikson
Journal:  Eur J Pediatr       Date:  1983-09       Impact factor: 3.183

5.  Non-infantile neuronopathic Gaucher's disease: a clinicopathologic study.

Authors:  M D Winkelman; B Q Banker; M Victor; H W Moser
Journal:  Neurology       Date:  1983-08       Impact factor: 9.910

6.  Changes in the fatty acid and sphingosine composition of the major gangliosides of human brain with age.

Authors:  J E Mansson; M T Vanier; L Svennerholm
Journal:  J Neurochem       Date:  1978-01       Impact factor: 5.372

7.  Gaucher disease--Norrbottnian type. I. General clinical description.

Authors:  S Dreborg; A Erikson; B Hagberg
Journal:  Eur J Pediatr       Date:  1980-03       Impact factor: 3.183

8.  Increased cerebroside concentration in plasma and erythrocytes in Gaucher disease: significant differences between type I and type III.

Authors:  O Nilsson; G Håkansson; S Dreborg; C G Groth; L Svennerholm
Journal:  Clin Genet       Date:  1982-11       Impact factor: 4.438

9.  Quantitative isolation of total glycosphingolipids from animal cells.

Authors:  T Saito; S I Hakomori
Journal:  J Lipid Res       Date:  1971-03       Impact factor: 5.922

10.  Lamellar bodies in Purkinje nerve cells experimentally induced by electric field.

Authors:  H A Hansson
Journal:  Brain Res       Date:  1981-07-06       Impact factor: 3.252

View more
  34 in total

Review 1.  The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders.

Authors:  Arash Velayati; W Haung Yu; Ellen Sidransky
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

2.  Reactions of vessel walls and brain parenchyma to the accumulation of Gaucher cells in the Norrbottnian type (type III) of Gaucher disease.

Authors:  N G Conradi; H Kalimo; P Sourander
Journal:  Acta Neuropathol       Date:  1988       Impact factor: 17.088

Review 3.  Astrocytes and lysosomal storage diseases.

Authors:  K V Rama Rao; T Kielian
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

4.  The increased sensitivity of neurons with elevated glucocerebroside to neurotoxic agents can be reversed by imiglucerase.

Authors:  D Pelled; H Shogomori; A H Futerman
Journal:  J Inherit Metab Dis       Date:  2000-03       Impact factor: 4.982

Review 5.  Multi-system disorders of glycosphingolipid and ganglioside metabolism.

Authors:  You-Hai Xu; Sonya Barnes; Ying Sun; Gregory A Grabowski
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

6.  Intravenous infusion of iPSC-derived neural precursor cells increases acid β-glucosidase function in the brain and lessens the neuronopathic phenotype in a mouse model of Gaucher disease.

Authors:  Yanyan Peng; Benjamin Liou; Venette Inskeep; Rachel Blackwood; Christopher N Mayhew; Gregory A Grabowski; Ying Sun
Journal:  Hum Mol Genet       Date:  2019-10-15       Impact factor: 6.150

7.  Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levels.

Authors:  You-Hai Xu; Rachel Reboulet; Brian Quinn; Joerg Huelsken; David Witte; Gregory A Grabowski
Journal:  Mol Genet Metab       Date:  2008-03-17       Impact factor: 4.797

8.  Modulating ryanodine receptors with dantrolene attenuates neuronopathic phenotype in Gaucher disease mice.

Authors:  Benjamin Liou; Yanyan Peng; Ronghua Li; Venette Inskeep; Wujuan Zhang; Brian Quinn; Nupur Dasgupta; Rachel Blackwood; Kenneth D R Setchell; Sheila Fleming; Gregory A Grabowski; John Marshall; Ying Sun
Journal:  Hum Mol Genet       Date:  2016-12-01       Impact factor: 6.150

9.  Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease.

Authors:  You-Hai Xu; Brian Quinn; David Witte; Gregory A Grabowski
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

10.  Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficits.

Authors:  Ying Sun; Benjamin Liou; Huimin Ran; Matthew R Skelton; Michael T Williams; Charles V Vorhees; Kazuyuki Kitatani; Yusuf A Hannun; David P Witte; You-Hai Xu; Gregory A Grabowski
Journal:  Hum Mol Genet       Date:  2010-01-04       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.